Hormonal
In individuals with type 2 diabetes who carry the haptoglobin (Hp) 2-2 phenotype AND have a history of cardiovascular disease, maintaining an HbA1c level of 8.0% or higher is associated with an increased risk of coronary artery disease compared to levels of 7.0-7.9%.
If you have type 2 diabetes, the haptoglobin 2-2 genetic variant, and a history of heart disease, keeping your HbA1c at 8.0% or higher may increase your risk of coronary events compared to keeping it between 7.0% and 7.9%. This highlights the importance of avoiding high blood sugar levels in this high-risk group.
Having HbA1c ≥ 8.0% was associated with CAD risk among participants with the Hp2-2 phenotype who had a history of CVD at baseline (1.79, 1.00-3.20; p, subgroup*HbA1c interaction = 0.13).
Why this rating
Subgroup analysis with a p-value for interaction of 0.13 (not statistically significant at 0.05), though the point estimate suggests increased risk.
Source
The relationship between repeated measurements of HbA1c and risk of coronary events among the common haptoglobin phenotype groups: the Action for Health in Diabetes (Look AHEAD) study
Allie S. Carew et al. · Cardiovascular Diabetology · 2024
DOI 10.1186/s12933-024-02448-z
More from this paper
- In individuals with type 2 diabetes who do not carry the haptoglobin (Hp) 2-2 phenotype, maintaining an HbA1c level below 6.5% is associated with a significantly lower risk of coronary artery disease compared to maintaining levels between 7.0% and 7.9%.Good
- In individuals with type 2 diabetes who carry the haptoglobin (Hp) 2-2 phenotype, maintaining an HbA1c level below 6.5% does NOT significantly reduce the risk of coronary artery disease compared to levels of 7.0-7.9%.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →